Northern Trust Corp Buys 82,817 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Northern Trust Corp raised its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 18.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 521,196 shares of the specialty pharmaceutical company's stock after buying an additional 82,817 shares during the quarter. Northern Trust Corp owned approximately 0.86% of Jazz Pharmaceuticals worth $64,185,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently bought and sold shares of JAZZ. Fuller & Thaler Asset Management Inc. boosted its stake in shares of Jazz Pharmaceuticals by 117.4% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company's stock valued at $115,681,000 after buying an additional 507,234 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Jazz Pharmaceuticals by 18.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock valued at $250,619,000 after purchasing an additional 320,724 shares in the last quarter. GMT Capital Corp raised its holdings in Jazz Pharmaceuticals by 140.0% in the 4th quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company's stock valued at $62,659,000 after acquiring an additional 296,800 shares during the last quarter. Tri Locum Partners LP purchased a new stake in shares of Jazz Pharmaceuticals during the 4th quarter valued at $19,927,000. Finally, Pacer Advisors Inc. increased its position in shares of Jazz Pharmaceuticals by 5.5% in the fourth quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company's stock worth $272,713,000 after acquiring an additional 115,102 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Insider Activity

In other news, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $116.35, for a total value of $116,350.00. Following the completion of the transaction, the chief executive officer now owns 439,307 shares of the company's stock, valued at approximately $51,113,369.45. This represents a 0.23 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Robert Iannone sold 7,080 shares of the business's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $138.60, for a total transaction of $981,288.00. Following the sale, the chief marketing officer now owns 82,024 shares in the company, valued at approximately $11,368,526.40. This trade represents a 7.95 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 28,236 shares of company stock valued at $3,956,190. Insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ traded down $0.60 during mid-day trading on Friday, hitting $97.81. The stock had a trading volume of 1,217,193 shares, compared to its average volume of 832,384. Jazz Pharmaceuticals plc has a 52 week low of $95.49 and a 52 week high of $148.06. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The business has a fifty day moving average price of $118.96 and a 200-day moving average price of $122.11. The firm has a market cap of $6.03 billion, a P/E ratio of 13.78, a PEG ratio of 1.04 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The firm had revenue of $897.84 million for the quarter, compared to the consensus estimate of $984.16 million. During the same period last year, the company posted $2.68 EPS. The business's revenue was down .5% on a year-over-year basis. On average, equities research analysts expect that Jazz Pharmaceuticals plc will post 16.96 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have commented on JAZZ shares. HC Wainwright increased their target price on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a report on Monday, March 10th. StockNews.com lowered Jazz Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Wednesday. Truist Financial raised their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. Morgan Stanley dropped their price target on shares of Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating on the stock in a research report on Wednesday. Finally, Wells Fargo & Company upgraded shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and increased their target price for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. One analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat, Jazz Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $182.79.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.